What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs), which account for 88% of FY26 revenue, with a smaller formulations business that reached break-even. Operations are anchored at a manufacturing facility in Tanuku, Andhra Pradesh, which is inspected by overseas regulators including the USFDA and Australia's TGA. The company sells APIs such as Metformin HCl and supplies them to generic drug partners in the US, with drug master files (DMFs) filed in the US and South Korea. New APIs are being added to the portfolio, including an anaesthetic API launched in Q4 FY26, with a stated plan to add four new molecules a year from FY27. Costs are dominated by raw materials at 42% of revenue, followed by employees at 18.4% and other operating expenses at 22.7%. A new 82%-owned Indian subsidiary, Wanbury Skin Health Limited, has been incorporated in the pharma space.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY25 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from WANBURY LIMITED's filed financials and exchange disclosures
WANBURY LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol WANBURY.
Yes. Over the trailing twelve months WANBURY LIMITED reported a net profit of ₹43 Cr on revenue of ₹630 Cr.
Not in the latest reported year — WANBURY LIMITED's dividend payout for FY25 was nil.
No. Debt stands at 2.92× equity, and it carries net debt of ₹169 Cr. That is lower than 1% of its 171 Pharmaceuticals peers.
On trailing P/E, WANBURY LIMITED ranks 49 of 169 in Pharmaceuticals — cheaper than 71% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session WANBURY LIMITED moves 1.69% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by WANBURY LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
